Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DO57XC
|
|||
| Drug Name |
AL001
|
|||
| Synonyms |
Latozinemab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Frontotemporal dementia [ICD-11: 6D83] | Phase 3 | [1] | |
| Company |
Alector
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sortilin (SORT1) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04374136) A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene. U.S.National Institutes of Health. | |||
| REF 2 | Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia. J Transl Med. 2023 Jun 15;21(1):387. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.